OrganoBiotech develops human-relevant Organ-on-a-Chip models integrated with machine learning to enhance drug discovery and development processes. By replicating complex human tissue environments, the company provides more accurate data for studying chronic diseases, significantly reducing the time and cost associated with traditional drug development methods.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug discovery and development methods often rely on cell cultures and animal models that fail to accurately replicate the complexities of human tissues, leading to inaccurate data and high failure rates in clinical trials. Studying chronic and multifactorial diseases is particularly challenging due to the limitations of these conventional models in mimicking the intricate environment of human tissues.
Solution
OrganoBiotech offers a platform that integrates human-relevant Organ-on-a-Chip models with machine learning to improve drug discovery and development. The company's OrganoPlatform enables the creation of customized, tissue-specific models that replicate the complex environment of human tissues. By using human organoids and organ-on-a-chip systems, OrganoBiotech's OrganoAssays provide data that more accurately reflect human physiological responses, bridging the gap between traditional models and human biology. The integration of machine learning with high-throughput organ-on-a-chip technology accelerates the development of OrganoDrugs, aiming for faster and more cost-effective drug validation.
Target Audience
The primary audience includes pharmaceutical companies, research institutions, and drug developers seeking more accurate and predictive preclinical models for drug discovery and toxicology screening.
Features
- OrganoPlatform: Enables the development of diverse, tissue-specific models with customization options.
- Scalable 3D perfusion tissue culture environment integrated with sensors for high-throughput screening.
- OrganoAssays: Functional assays to study complex, progressive, and multifactorial diseases.
- Human organoids and organ-on-a-chip systems that mimic the native human tissue environment.
- Capabilities for toxicology screening, high content screening, and preclinical drug testing.
- IFlowPlate384, AngioPlate384, and UniPlate384 platforms for 3D tissue and organoid culture.
- Supporting equipment such as IFlowRocker, AngioTEER, and AeroLung.